CAJ | 학술논문

目的评价经动脉化疗栓塞(TACE)联合索拉非尼治疗大肝癌的疗效与安全性.方法回顾分析中山大学附属第一医院2008年7月至2012年6月收治的79例大肝癌(直径＞ 10 cm)患者的临床资料,分为3组,24例行TACE联合索拉非尼治疗(T+S组),35例行单纯TACE治疗(T组),20例单纯服用索拉非尼治疗(S组).结果 T+S组、T组、S组中位生存期(MST)分别为15、10、5个月(P =0.000)；3组的中位肿瘤进展时间(TTP)分别为6.0、3.0、2.5个月(P=0.000),T+S组与S组的索拉非尼相关不良反应的发生率差异无统计学意义(P＞0.05),主要为手足皮肤反应、腹泻和脱发,无4级以上的严重不良反应.T+S组与T组的介入治疗相关并发症发生率差异无统计学意义(P＞0.05),主要为轻度的黄疸、腹水和腹股沟血肿.结论 TACE联合索拉非尼治疗大肝癌安全性和耐受性良好,可有效控制肿瘤进展,延长患者生存期.
목적 평개경동맥화료전새(TACE)연합색랍비니치료대간암적료효여안전성.방법 회고분석중산대학부속제일의원2008년7월지2012년6월수치적79례대간암(직경＞ 10 cm)환자적림상자료,분위3조,24례행TACE연합색랍비니치료(T+S조),35례행단순TACE치료(T조),20례단순복용색랍비니치료(S조).결과 T+S조、T조、S조중위생존기(MST)분별위15、10、5개월(P =0.000)；3조적중위종류진전시간(TTP)분별위6.0、3.0、2.5개월(P=0.000),T+S조여S조적색랍비니상관불량반응적발생솔차이무통계학의의(P＞0.05),주요위수족피부반응、복사화탈발,무4급이상적엄중불량반응.T+S조여T조적개입치료상관병발증발생솔차이무통계학의의(P＞0.05),주요위경도적황달、복수화복고구혈종.결론 TACE연합색랍비니치료대간암안전성화내수성량호,가유효공제종류진전,연장환자생존기.
Objective To evaluate the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma.Methods 79 patients with large HCC (larger than 10 cm in diameter)were enrolled from July 2008 to June 2012 for this retrospective study.24 patients undertaken TACE combined with sorafenib as T + S group.35 patients undertaken TACE alone as T group,and other 20 patients treated with sorafenib alone as S group.Results The median survival time was 15 months in T + S group,10 months in T group,and 5 months in S group,respectively (P =0.000).The median time of tumor progress was 6 months,3 months and 2.5 months,respectively(P =0.000).The most common adverse events related to sorafenib in group T + S group and S group alone were hand foot skin reaction,diarrhea and alopecia.The incidence rate of adverse events related to sorafenib was no significant difference between two groups.There was no 4 or more grade adverse event occurred in each group.The most common complications related to interventional treatment in group T + S group and T group alone were mild jaundice,ascites,inguinal region hematoma.The incidence rate of complications related to interventional treatment was no significant difference between two groups.Conclusion The combination of TACE and sorafenib in patients with large HCC is well tolerated and safe,which is available to delay tumor progression and prolong survival.